Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | CD81 | P60033 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9069441 | 0.98 | ACACB (0.37) | ACACBACACAFFAR1FFAR4USP2 | |
| SCHEMBL9069444 | 0.98 | ACACB (0.37) | ACACBACACAFFAR1FFAR4USP2 | |
| SCHEMBL2680665 | 0.86 | EP300 (0.42) | ACACBACACAFFAR1FFAR4USP2 | |
| SCHEMBL29225685 | 0.86 | EP300 (0.42) | ACACBACACAFFAR1FFAR4USP2 | |
| SCHEMBL11676809 | 0.86 | EP300 (0.42) | ACACBACACAFFAR1FFAR4USP2 | |
| SCHEMBL11676799 | 0.86 | EP300 (0.42) | ACACBACACAFFAR1FFAR4USP2 | |
| SCHEMBL245743 | 0.85 | CD81 (0.38) | ACACAALDH1A1CD81 | |
| SCHEMBL474809 | 0.85 | CD81 (0.38) | ACACAALDH1A1CD81 | |
| SCHEMBL10593196 | 0.85 | FFAR1 (0.54) | FFAR1FFAR4EP300GPR84FAAH | |
| SCHEMBL6060163 | 0.85 | FFAR1 (0.46) | ACACBACACAFFAR1FFAR4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3530270-B1 | MUCOSAL IMMUNOMODULATOR | YAMADA BEE CO INC (JP) | 2024-08-07 | — | — | EP | disclosed |
| US-11089805-B2 | Mucosal immunomodulator | YAMADA BEE COMPANY, INC. (JP) | 2021-08-17 | — | — | US | disclosed |
| EP-3530270-A1 | MUCOSAL IMMUNOMODULATOR | Yamada Bee Company, Inc. (JP) | 2019-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11089805-B2 | Mucosal immunomodulator | MUC1, TSLP, CD74 | ACACB 2806/4885ACACA 2950/4885FFAR1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.